HC Wainwright & Co. Reiterates Buy on Annovis Bio, Maintains $40 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Annovis Bio (NYSE:ANVS) and maintained a $40 price target.
August 15, 2023 | 10:54 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a 'Buy' rating on Annovis Bio and maintained a $40 price target, which could positively impact the stock in the short term.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. The maintained price target of $40 also indicates their confidence in the stock's potential, which could drive buying interest and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100